JP2015520142A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520142A5 JP2015520142A5 JP2015510815A JP2015510815A JP2015520142A5 JP 2015520142 A5 JP2015520142 A5 JP 2015520142A5 JP 2015510815 A JP2015510815 A JP 2015510815A JP 2015510815 A JP2015510815 A JP 2015510815A JP 2015520142 A5 JP2015520142 A5 JP 2015520142A5
- Authority
- JP
- Japan
- Prior art keywords
- solution
- esmolol hydrochloride
- formulation
- ready
- saline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000243 solution Substances 0.000 claims 13
- 238000009472 formulation Methods 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- VZTMYLWJKCAXMZ-UHFFFAOYSA-N 2-[(2-chloroquinazolin-4-yl)amino]ethanol Chemical compound C1=CC=C2C(NCCO)=NC(Cl)=NC2=C1 VZTMYLWJKCAXMZ-UHFFFAOYSA-N 0.000 claims 10
- 229960001015 esmolol hydrochloride Drugs 0.000 claims 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- 239000008215 water for injection Substances 0.000 claims 5
- 238000001802 infusion Methods 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000008176 lyophilized powder Substances 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000001953 Hypotension Diseases 0.000 claims 2
- 239000008156 Ringer's lactate solution Substances 0.000 claims 2
- 208000001871 Tachycardia Diseases 0.000 claims 2
- 230000036543 hypotension Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000006794 tachycardia Effects 0.000 claims 2
- 206010000489 Acidosis hyperchloraemic Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010003662 Atrial flutter Diseases 0.000 claims 1
- 208000002251 Dissecting Aneurysm Diseases 0.000 claims 1
- 208000029422 Hypernatremia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 239000012891 Ringer solution Substances 0.000 claims 1
- 208000007888 Sinus Tachycardia Diseases 0.000 claims 1
- 206010040893 Skin necrosis Diseases 0.000 claims 1
- 208000003734 Supraventricular Tachycardia Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010002895 aortic dissection Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
- 206010047302 ventricular tachycardia Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12167443 | 2012-05-10 | ||
| EP12167443.6 | 2012-05-10 | ||
| PCT/EP2013/059594 WO2013167657A1 (en) | 2012-05-10 | 2013-05-08 | Parenteral esmolol formulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520142A JP2015520142A (ja) | 2015-07-16 |
| JP2015520142A5 true JP2015520142A5 (enExample) | 2016-06-09 |
| JP6220383B2 JP6220383B2 (ja) | 2017-10-25 |
Family
ID=48407551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510815A Active JP6220383B2 (ja) | 2012-05-10 | 2013-05-08 | 非経口エスモロール製剤 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20150087704A1 (enExample) |
| EP (1) | EP2846776B1 (enExample) |
| JP (1) | JP6220383B2 (enExample) |
| CN (1) | CN104379134A (enExample) |
| AU (1) | AU2013258031B2 (enExample) |
| BR (1) | BR112014027870B1 (enExample) |
| CA (1) | CA2872953C (enExample) |
| CL (1) | CL2014003028A1 (enExample) |
| DK (1) | DK2846776T3 (enExample) |
| EA (1) | EA032344B1 (enExample) |
| ES (1) | ES2794093T3 (enExample) |
| HR (1) | HRP20200897T1 (enExample) |
| HU (1) | HUE049314T2 (enExample) |
| IL (1) | IL235497A0 (enExample) |
| LT (1) | LT2846776T (enExample) |
| MA (1) | MA37500B1 (enExample) |
| MX (1) | MX374771B (enExample) |
| MY (1) | MY173900A (enExample) |
| NZ (1) | NZ701429A (enExample) |
| PH (1) | PH12014502494B1 (enExample) |
| PL (1) | PL2846776T3 (enExample) |
| PT (1) | PT2846776T (enExample) |
| SI (1) | SI2846776T1 (enExample) |
| TN (1) | TN2014000464A1 (enExample) |
| UA (1) | UA115333C2 (enExample) |
| WO (1) | WO2013167657A1 (enExample) |
| ZA (1) | ZA201408149B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019122157A1 (en) * | 2017-12-21 | 2019-06-27 | Ipsol Ag | A lyophilisate comprising esmolol and adenosine for use in cardioplegia |
| CN111848420A (zh) * | 2020-07-22 | 2020-10-30 | 杭州煌森生物科技有限公司 | 一种盐酸艾司洛尔的新晶型及制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6310094B1 (en) * | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
| TWI277414B (en) | 2001-01-12 | 2007-04-01 | Baxter Int | Esmolol formulation |
| SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| JPWO2007026771A1 (ja) * | 2005-08-31 | 2009-03-12 | 小野薬品工業株式会社 | 点滴用注射剤 |
| US20080293814A1 (en) | 2007-05-22 | 2008-11-27 | Deepak Tiwari | Concentrate esmolol |
| DK2234614T3 (da) | 2007-12-21 | 2013-02-11 | Aop Orphan Pharmaceuticals Ag | Farmaceutisk sammensætning til parenteral administration af et ultrakort virkende beta-receptorblokerende middel |
| CN102106846A (zh) * | 2009-12-23 | 2011-06-29 | 南京海辰药业有限公司 | 左旋盐酸艾司洛尔药物组合物及其制备方法 |
-
2013
- 2013-05-08 CA CA2872953A patent/CA2872953C/en active Active
- 2013-05-08 US US14/398,312 patent/US20150087704A1/en not_active Abandoned
- 2013-05-08 DK DK13721740.2T patent/DK2846776T3/da active
- 2013-05-08 EA EA201491841A patent/EA032344B1/ru not_active IP Right Cessation
- 2013-05-08 MY MYPI2014703249A patent/MY173900A/en unknown
- 2013-05-08 AU AU2013258031A patent/AU2013258031B2/en active Active
- 2013-05-08 HR HRP20200897TT patent/HRP20200897T1/hr unknown
- 2013-05-08 NZ NZ701429A patent/NZ701429A/en unknown
- 2013-05-08 PT PT137217402T patent/PT2846776T/pt unknown
- 2013-05-08 MX MX2014013556A patent/MX374771B/es active IP Right Grant
- 2013-05-08 CN CN201380028099.XA patent/CN104379134A/zh active Pending
- 2013-05-08 BR BR112014027870-9A patent/BR112014027870B1/pt active IP Right Grant
- 2013-05-08 HU HUE13721740A patent/HUE049314T2/hu unknown
- 2013-05-08 ES ES13721740T patent/ES2794093T3/es active Active
- 2013-05-08 WO PCT/EP2013/059594 patent/WO2013167657A1/en not_active Ceased
- 2013-05-08 PL PL13721740T patent/PL2846776T3/pl unknown
- 2013-05-08 LT LTEP13721740.2T patent/LT2846776T/lt unknown
- 2013-05-08 EP EP13721740.2A patent/EP2846776B1/en active Active
- 2013-05-08 JP JP2015510815A patent/JP6220383B2/ja active Active
- 2013-05-08 SI SI201331732T patent/SI2846776T1/sl unknown
- 2013-05-08 UA UAA201413014A patent/UA115333C2/uk unknown
-
2014
- 2014-10-31 TN TN2014000464A patent/TN2014000464A1/fr unknown
- 2014-11-04 IL IL235497A patent/IL235497A0/en active IP Right Grant
- 2014-11-05 MA MA37500A patent/MA37500B1/fr unknown
- 2014-11-07 ZA ZA2014/08149A patent/ZA201408149B/en unknown
- 2014-11-07 PH PH12014502494A patent/PH12014502494B1/en unknown
- 2014-11-07 CL CL2014003028A patent/CL2014003028A1/es unknown
-
2017
- 2017-07-28 US US15/663,645 patent/US20170326095A1/en not_active Abandoned
-
2022
- 2022-01-24 US US17/582,945 patent/US11963940B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022116191A (ja) | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 | |
| RU2010114042A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010113986A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010114024A (ru) | Применение гонадорелина в качестве терапевтического средства | |
| RU2010113989A (ru) | Применение пептида в качестве терапевтического средства | |
| JP2010511715A5 (enExample) | ||
| JP2013537212A5 (enExample) | ||
| RU2010113998A (ru) | Применение пептида rfmwmr в качестве терапевтического средства | |
| ES2324009B1 (es) | Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo. | |
| FI2988750T4 (fi) | Landiololihydrokloridin käyttö takyarytmioiden pitkäaikaishoidossa | |
| JP2015520142A5 (enExample) | ||
| CN103054883B (zh) | 一种含有果糖二磷酸钠化合物的药物组合物 | |
| CN108815171B (zh) | 25-羟基胆固醇在制备治疗或预防心肌梗死的药物中的应用 | |
| HRP20200897T1 (hr) | Parenteralna formulacija esmolola | |
| RU2012116226A (ru) | Бронхолитическое средство на основе простагландина | |
| CN103340863A (zh) | 烟酰胺在制备治疗糖尿病伤口愈合药物中的应用 | |
| WO2019152765A1 (en) | N-acetylcysteine attenuates aortic stenosis progression by inhibiting shear-mediated tgf-beta activation and signaling | |
| WO2022233310A1 (zh) | 丹酚酸a盐水合物、其制备方法及用途 | |
| WO2015020139A1 (ja) | ナノ粒子及びナノ粒子組成物並びにその製造方法 | |
| CN116785435B (zh) | Ep3受体拮抗剂l-798106在制备预防心肌缺血再灌注损伤药物中的应用 | |
| CN112209834A (zh) | 一种有机亚硝酸根供体及其制备方法与医药用途 | |
| CN104173343B (zh) | 一种米力农化合物及含有该化合物的药物组合物 | |
| JP2010248263A (ja) | 塩酸ランジオロールを含有する頻脈性不整脈の治療剤 | |
| HK40067136A (zh) | 含有对二羟硼基苯丙氨酸的注射液剂 | |
| WO2023023995A1 (zh) | 一种防治心肌缺血后心功能衰竭的药物及其应用 |